Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue MISSISSAUGA, ON, May 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May...

Mark Beaudet expected to be appointed new independent Chair of Board MISSISSAUGA, ON, April 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that it has completed an amendment to the securities purchase agreement (the "Amendment") with investment funds...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted,...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017. Q4 AND YEAR-END 2016 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR) ("Cipher" or "the Company") today announced that its Board of Directors has approved the voluntary withdrawal of its common shares from NASDAQ...